SCHEMBL20152022

SCHEMBL20152022

CCNC(=O)c1ccc(Cl)nn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
CNR1 P21554 1/20 0.40
LMNA P02545 3/20 0.40
MAOB P27338 1/20 0.38
GABRA1 P14867 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALOX15 P16050 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 1/20 0.37
PARP1 P09874 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8310937 0.86 NPC1 (0.47) JUNNFKB1NFKB2RELALMNA
SCHEMBL937430 0.82 NAAA (0.50) CNR1KDM4EALOX15HTTL3MBTL1
SCHEMBL8310344 0.82 JUN (0.48) JUNNFKB1NFKB2RELACNR1
SCHEMBL20460443 0.81 HPGD (0.49) JUNNFKB1NFKB2RELALMNA
SCHEMBL20460466 0.81 JUN (0.48) JUNNFKB1NFKB2RELALMNA
SCHEMBL938874 0.81 NAAA (0.52) CNR1LMNAKDM4EL3MBTL1HPGD
SCHEMBL18896207 0.81 NAAA (0.52) CNR1LMNAKDM4EL3MBTL1HPGD
SCHEMBL937478 0.81 NAAA (0.52) CNR1LMNAKDM4EL3MBTL1HPGD
SCHEMBL8308548 0.80 HPGD (0.54) JUNNFKB1NFKB2RELALMNA
SCHEMBL936146 0.80 JUN (0.47) JUNNFKB1NFKB2RELALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10369140-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-08-06 US disclosed
US-20180133198-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133198-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 JUN 3516/4885NFKB1 3678/4885NFKB2 3759/4885
US-10369140-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors DGAT2, MGAT2, MGAT1 JUN 3516/4885NFKB1 3678/4885NFKB2 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.